What are the differences between the Model for End‑Stage Liver Disease 3.0 (MELD‑3.0) score and the Model for End‑Stage Liver Disease Sodium (MELD‑Na) score?

MELD 3.0 vs. MELD-Na: Key Differences

MELD 3.0 is a superior mortality prediction model that adds sex and albumin as variables, recalibrates creatinine weighting with a 3.0 mg/dL cap, and incorporates interaction terms between bilirubin-sodium and albumin-creatinine, resulting in better discrimination and reduced waitlist mortality compared to MELD-Na. 1, 2

Core Structural Differences

Variables Included

MELD-Na contains:

• Bilirubin
• INR (international normalized ratio)
• Creatinine
• Sodium

MELD 3.0 adds:

• Female sex (credits an extra 1.3 points to women on average)
• Serum albumin
• Interaction terms between bilirubin and sodium, and between albumin and creatinine
• Creatinine cap at 3.0 mg/dL (versus 4.0 mg/dL in MELD-Na) 1, 2

Mathematical Weighting

MELD 3.0 uses refit coefficients that more accurately weigh creatinine in predicting 90-day mortality. The recalibration was based on contemporary US national registry data (January 2016-December 2018), making it more relevant to current patient populations 2.

Performance Differences

Mortality Prediction Accuracy

MELD 3.0 demonstrates statistically superior discrimination:

• C-statistic: 0.869 vs. 0.862 (p <0.01) 1, 2
• Correctly reclassified a net 8.8% of patients to a higher MELD tier, particularly benefiting women 1, 2

Clinical Impact on Waitlist Mortality

Using the Liver Simulated Allocation Model, MELD 3.0 resulted in:

• Fewer waitlist deaths: 7,788 vs. 7,850 (p = 0.02) 1, 2
• This represents a 2.7% reduction in waitlist mortality in validation studies 3

Gender Equity Implications

The Critical Difference

MELD-Na systematically underestimates mortality risk in women because serum creatinine-based models fail to account for lower muscle mass in women, leading to underestimation of renal dysfunction 1. This contributes to women having:

• 17-30% less likelihood of undergoing liver transplantation
• 30% greater likelihood of dying on the waitlist 1

MELD 3.0 directly addresses this disparity by:

• Including female sex as an independent variable
• Providing an average 1.3-point bonus to women 1
• Affording women a meaningfully higher chance of transplantation through correct reclassification 2

Limitations of Gender Correction

While MELD 3.0 improves equity, the benefit may be less pronounced in patients with MELD >30 and in regions with severe organ shortage where living donor liver transplantation predominates 3. The 2024 EASL guidelines note that other models like GEMA (Gender-Equity Model for Liver Allocation) may eliminate gender disparities more completely 1.

Clinical Application Context

When MELD 3.0 Matters Most

The differences between MELD 3.0 and MELD-Na are most clinically significant for:

• Female patients (particularly those with borderline MELD scores)
• Patients with hypoalbuminemia (common in cirrhosis with severe ascites)
• Patients with moderate renal dysfunction (creatinine 2.0-4.0 mg/dL range, where the cap difference matters)

Allocation System Implementation

MELD 3.0 was developed specifically to replace MELD-Na for deceased donor liver allocation in the United States 4, 2. The 2024 EASL guidelines recommend implementing new allocation systems to address compromised access of women to liver transplantation 1.

Important Caveats

Measurement Considerations

Sodium assay method matters: Different ion-selective electrode methods (direct vs. indirect) can produce significantly different MELD-Na scores, with 40% of patients potentially moving up and 18% moving down on the waitlist based on assay method alone 5. This technical issue affects both MELD-Na and MELD 3.0.

Regional Variations

In regions with severe organ shortage where living donor liver transplantation predominates (e.g., Korea), the predicted benefit of MELD 3.0 over MELD-Na may be limited to 2.7% reduction in waitlist mortality 3. The model was derived from US data where deceased donor transplantation is more common.

Beyond Allocation

The utility of MELD 3.0 for risk stratification in other clinical scenarios (major abdominal surgery, TIPS placement, acute variceal bleeding) requires further validation 4, though early data suggest MELD 3.0 outperforms MELD-Na for predicting 6-week mortality in acute variceal bleeding (AUROC 0.81 vs. 0.75) 6.

Practical Algorithm for Score Selection

Use MELD 3.0 when:

• Prioritizing patients for deceased donor liver transplantation
• Evaluating female candidates (mandatory to address gender disparity)
• Patients have hypoalbuminemia or moderate renal dysfunction
• Contemporary mortality prediction is needed

MELD-Na may still be used when:

• Local allocation systems have not yet adopted MELD 3.0
• Comparing historical cohorts or published literature using MELD-Na
• Regional validation of MELD 3.0 is pending